Seeing Is Believing
Currently out of the existing stock ratings of Mason Carrico, 32 are a BUY (88.89%), 4 are a HOLD (11.11%).
Analyst Mason Carrico works at STEPHENS with a stock forecast success ratio of 32.78% fulfilled within 39.83 days on average.
Mason Carrico’s has documented 71 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ILMN, Illumina at 14-Feb-2024.
Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 5/24/2022. The price target of $25 was fulfilled within 16 days with a profit of $5.31 (26.97%) receiving and performance score of 16.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
37
$14.16 (62.00%)
32
2 months 2 days ago
3/9 (33.33%)
$17.06 (85.56%)
29
Buy
28
$5.16 (22.59%)
37
2 months 2 days ago
2/5 (40%)
$8.06 (40.42%)
22
Buy
35
$12.16 (53.24%)
40
4 months 14 days ago
1/5 (20%)
$13.92 (66.03%)
70
Buy
32
$9.16 (40.11%)
32
9 months 26 days ago
0/5 (0%)
$11.7 (57.64%)
Buy
30
$7.16 (31.35%)
35
10 months 18 days ago
3/4 (75%)
$16.6 (123.88%)
44
Which stock is Mason Carrico is most bullish on?
Which stock is Mason Carrico is most reserved on?
What Year was the first public recommendation made by Mason Carrico?